• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转甲状腺素蛋白心脏淀粉样变的肺部受累:一例报告

Pulmonary involvement in transthyretin cardiac amyloidosis: a case report.

作者信息

Kellens Michiel, Nijst Petra, Ameloot Koen, Mullens Wilfried, Bertrand Philippe, Jannis Levi, Van Dorpe Jo, Dupont Matthias

机构信息

University of Antwerp, Prinsstraat 13, 2000 Antwerp, Belgium.

Ziekenhuis Oost Limburg, University Hasselt, Synapspark 1, 3600 Genk, Belgium.

出版信息

Eur Heart J Case Rep. 2024 Nov 9;8(11):ytae568. doi: 10.1093/ehjcr/ytae568. eCollection 2024 Nov.

DOI:10.1093/ehjcr/ytae568
PMID:39687736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11648963/
Abstract

BACKGROUND

Amyloidosis is a systemic disorder characterized by the deposition of misfolded proteins in various organs. While cardiac transthyretin amyloidosis (ATTR) is well-recognized, pulmonary involvement is rare and often overlooked in clinical practice.

CASE SUMMARY

We present a case of severe, and ultimately fatal, cardiac and pulmonary ATTR amyloidosis in a 67-year-old male. The patient's initial complaints included dyspnoea and exercise intolerance. Echocardiography revealed isolated concentric left ventricular hypertrophy, and subsequent cardiac MRI suggested cardiac amyloidosis. Additional diagnostic steps, including bone scan and endomyocardial tissue biopsy, confirmed the diagnosis of ATTR amyloidosis. Intriguingly, this case also unveiled concurrent pulmonary involvement, characterized by ground-glass opacities, lymphadenopathy, and impaired lung function. Despite treatment with tafamidis, the patient's condition deteriorated swiftly. He was admitted to the hospital four months after his initial presentation, and ultimately succumbed to therapy-resistant respiratory distress and heart failure. Post-mortem examination revealed extensive cardiac and pulmonary interstitial ATTR amyloidosis, with the lung exhibiting a fibrotic stage of diffuse alveolar damage.

DISCUSSION

This case highlights pulmonary involvement as a potential contributor to the clinical picture of ATTR amyloidosis. It also emphasizes the necessity for a multidisciplinary approach, heightened awareness, and further research to enhance the detection and management of pulmonary involvement in ATTR amyloidosis.

摘要

背景

淀粉样变性是一种全身性疾病,其特征是错误折叠的蛋白质在各个器官中沉积。虽然心脏转甲状腺素蛋白淀粉样变性(ATTR)已广为人知,但肺部受累情况罕见,在临床实践中常被忽视。

病例摘要

我们报告一例67岁男性严重且最终致命的心脏和肺部ATTR淀粉样变性病例。患者最初的症状包括呼吸困难和运动不耐受。超声心动图显示孤立的同心性左心室肥厚,随后的心脏磁共振成像提示心脏淀粉样变性。包括骨扫描和心内膜组织活检在内的进一步诊断步骤确诊为ATTR淀粉样变性。有趣的是,该病例还发现同时存在肺部受累,表现为磨玻璃影、淋巴结肿大和肺功能受损。尽管使用了塔法米迪斯进行治疗,但患者病情迅速恶化。他在初次就诊四个月后入院,最终死于难治性呼吸窘迫和心力衰竭。尸检显示广泛的心脏和肺部间质ATTR淀粉样变性,肺部呈现弥漫性肺泡损伤的纤维化阶段。

讨论

该病例突出了肺部受累是ATTR淀粉样变性临床症状的一个潜在因素。它还强调了采取多学科方法、提高认识以及进一步研究以加强对ATTR淀粉样变性肺部受累的检测和管理的必要性。

相似文献

1
Pulmonary involvement in transthyretin cardiac amyloidosis: a case report.转甲状腺素蛋白心脏淀粉样变的肺部受累:一例报告
Eur Heart J Case Rep. 2024 Nov 9;8(11):ytae568. doi: 10.1093/ehjcr/ytae568. eCollection 2024 Nov.
2
Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.与Pro24Ser转甲状腺素蛋白突变相关的遗传性心脏淀粉样变性:一例报告
J Med Case Rep. 2018 Dec 16;12(1):370. doi: 10.1186/s13256-018-1931-5.
3
A case report of transthyretin amyloidosis following cardiac transplantation: thick ventricles that look alike.心脏移植后转甲状腺素蛋白淀粉样变性病例报告:相似的增厚心室。
Eur Heart J Case Rep. 2024 May 8;8(8):ytae242. doi: 10.1093/ehjcr/ytae242. eCollection 2024 Aug.
4
Physical Examination as a Clue to Transthyretin Cardiac Amyloidosis: A Case Report.体格检查作为转甲状腺素蛋白心脏淀粉样变的线索:一例报告
Cureus. 2023 Aug 3;15(8):e42925. doi: 10.7759/cureus.42925. eCollection 2023 Aug.
5
Clinical, radiologic, and pathologic features and outcomes of pulmonary transthyretin amyloidosis.甲状腺转运蛋白肺淀粉样变性的临床、放射学和病理学特征及预后
Respir Med. 2022 Apr;194:106761. doi: 10.1016/j.rmed.2022.106761. Epub 2022 Feb 8.
6
Clinical clues for suspecting wild-type transthyretin cardiac amyloidosis in patients with monoclonal gammopathy of undetermined significance: a case report.意义未明的单克隆丙种球蛋白病患者疑似野生型转甲状腺素蛋白心脏淀粉样变性的临床线索:一例报告
Egypt Heart J. 2024 Jun 10;76(1):74. doi: 10.1186/s43044-024-00499-x.
7
Conjunctival lymphangiectasia and retinal angiopathy in hereditary transthyretin amyloidosis.遗传性转甲状腺素蛋白淀粉样变性中的结膜淋巴管扩张和视网膜血管病变。
Int J Retina Vitreous. 2022 Jan 6;8(1):4. doi: 10.1186/s40942-021-00357-x.
8
Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.由淀粉样前体蛋白转甲状腺素蛋白V122I变体引起的散发性心脏淀粉样变性
Int Heart J. 2019 Nov 30;60(6):1441-1443. doi: 10.1536/ihj.19-134. Epub 2019 Oct 31.
9
Heart of the Matter: Decoding the Underdiagnosed Cardiac Amyloidosis.问题的核心:解读未被充分诊断的心脏淀粉样变性
Cureus. 2023 Dec 14;15(12):e50527. doi: 10.7759/cureus.50527. eCollection 2023 Dec.
10
Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.心肌ATTR 淀粉样变的诊断和治疗进展。
Heart Fail Rev. 2019 Jul;24(4):521-533. doi: 10.1007/s10741-019-09776-3.

本文引用的文献

1
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.抗心肌转甲状腺素蛋白抗体 NI006 用于清除心脏淀粉样变性的 1 期临床试验。
N Engl J Med. 2023 Jul 20;389(3):239-250. doi: 10.1056/NEJMoa2303765. Epub 2023 May 20.
2
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.2023年美国心脏病学会关于心脏淀粉样变性患者综合多学科护理的专家共识决策路径:美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. doi: 10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23.
3
Hemodynamic Profiling and Prognosis in Cardiac Amyloidosis.
心脏淀粉样变性的血流动力学分析与预后
Circ Heart Fail. 2023 Mar;16(3):e010078. doi: 10.1161/CIRCHEARTFAILURE.122.010078. Epub 2023 Jan 25.
4
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.转甲状腺素蛋白淀粉样心肌病在射血分数保留的心力衰竭中的患病率。
JAMA Cardiol. 2021 Nov 1;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070.
5
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗:欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
6
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.淀粉样变命名 2020:国际淀粉样变协会(ISA)命名委员会的更新和建议。
Amyloid. 2020 Dec;27(4):217-222. doi: 10.1080/13506129.2020.1835263. Epub 2020 Oct 26.
7
A new staging system for cardiac transthyretin amyloidosis.心脏转甲状腺素蛋白淀粉样变性的新分期系统。
Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.
8
The lung in amyloidosis.淀粉样变性中的肺脏。
Eur Respir Rev. 2017 Sep 6;26(145). doi: 10.1183/16000617.0046-2017. Print 2017 Sep 30.
9
Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases.肺淀粉样变性的临床相关性:对76例尸检病例的分析
Eur Respir J. 2017 Feb 23;49(2). doi: 10.1183/13993003.02313-2016. Print 2017 Feb.
10
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.野生型转甲状腺素蛋白心脏淀粉样变性的自然病史和使用新型分期系统进行风险分层。
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. doi: 10.1016/j.jacc.2016.06.033.